Intermediate for Venetoclax. Venetoclax (trade name Venclexta) is a small molecule oral drug that treats chronic lymphocytic leukemia (CLL) in those with a specific chromosomal abnormality. Venetoclax is a BH3-mimetic and acts as a Bcl-2 inhibitor. Venetoclax has been approved by US FDA om April 11, 2016.
Product Name: Ethyl 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)benzoate
CAS Number: 1630101-59-5
Molecular Weight:  599.1711
Molecular Formula:  C35H39ClN4O3
Purity (HPLC): ≥95%
Shipping Conditions: Room temperature.
Storage Conditions: Refrigerated.
Regulatory Statement:  For Research Use Only.